Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Lorraine Cafuir"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Abstract Background Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. Case presentation
Externí odkaz:
https://doaj.org/article/7db9860045fb4a8d8c51c363e19dccf4
Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia
Autor:
Stacey A. Fedewa, Tyler W. Buckner, Sara Guasch Parks, Duc Q. Tran, Lorraine Cafuir, Ana G. Antun, Shanna Mattis, Christine L. Kempton
Publikováno v:
Journal of Racial and Ethnic Health Disparities.
Autor:
Sara Guasch Parks, Stacey Fedewa, Tyler Buckner, Ana G Antun, Lorraine Cafuir, Duc Q Tran, Shanna Mattis, Christine L Kempton
Publikováno v:
Blood. 140:8005-8007
Autor:
Stacey Fedewa, Tyler Buckner, Duc Q Tran, Lorraine Cafuir, Ana G Antun, Shanna Mattis, Christine L Kempton
Publikováno v:
Blood. 140:1232-1233
Autor:
Lorraine Cafuir, Adina Estrin, Er Chen, David Hinds, Patricia Prince, Jennifer Thorburn, Henry Mead, Christine L. Kempton
To assess real-world use of emicizumab in adult people with hemophilia A (PwHA) without inhibitors including healthcare resource utilization (HCRU) and costs. Adult, male PwHA without inhibitors initiating emicizumab (index date) were identified usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11f4f02a1db68993100afcce4c6aced8
Publikováno v:
Expert Review of Hematology. 12:515-524
Introduction: Hemophilia A (HA) is an inherited bleeding disorder that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as well as life-threatening bleeds including intracranial hemorrhage. For deca
Autor:
Christine L. Kempton, Lorraine Cafuir
Publikováno v:
Therapeutic Advances in Hematology. 8:303-313
Hemophilia A is a congenital X-linked bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Routine infusion of factor replacement products is the current standard of care; however, the development of alloantibodies against FVIII re
Publikováno v:
Thrombosis research. 189
Background:Direct oral anticoagulants (DOAC) are now a mainstay of anticoagulant therapy. However, outside of clinical trials, reports on treatment of DOAC-related bleeding are limited. We report a retrospective cohort study of the management and out
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Background Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. Case presentation A 42 year
Publikováno v:
FEBS Journal. 274:3429-3439
The runt family transcriptional regulator, Runx3, is upregulated during the differentiation of CD8 single-positive thymocytes and is expressed in peripheral CD8+ T cells. Mice carrying targeted deletions in Runx3 have severe defects in the developmen